Cyclacel制药 CYCC 深 沪
已收盘 09-11 16:00:00 美东时间
6.365
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 6.365
- 总市值 1008.22万
- 52周最高 597.60
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.0801
- 委 比 0.00%
- 总股本 158.40万
- 历史最高 7067520.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 40.944
- 每 手 1
- 风险率 1.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cyclacel Pharmaceuticals: Recent Acquisition Completed
An update from Cyclacel Pharmaceuticals ( ($CYCC) ) is now available. On Septem...
09-12 18:28
Cyclacel Pharmaceuticals Approves Key Shareholder Proposals
Cyclacel Pharmaceuticals ( ($CYCC) ) has provided an update. On September 4, 20...
09-06 00:18
Cyclacel Pharmaceuticals Enters Warrant Exchange Agreement
Cyclacel Pharmaceuticals ( ($CYCC) ) has provided an update. On September 4, 20...
09-05 04:40
Cyclacel Pharmaceuticals Exchanges Series C Warrants For 559,395 Common Shares In Agreement With Accredited Investors
On September 4, 2025, Cyclacel Pharmaceuticals, Inc. (the "Company") entered into a Warrant Exchange Agreement (the "Exchange Agreement") with certain accredited investors (the "Holders") of existing Series C common
09-05 04:03
Cyclacel Pharmaceuticals declares $0.15 dividend
Cyclacel Pharmaceuticals (NASDAQ:CYCC) declares $0.15/share quarterly dividend, in line with previous. Forward yield 6.75% Payable May 1; for shareholders of record April 29; ex-div April 29. See CYCC...
08-14 13:25
Cyclacel Pharmaceuticals Implements Reverse Stock Split in July
An announcement from Cyclacel Pharmaceuticals ( ($CYCC) ) is now available. Cyc...
08-14 05:55
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Cyclacel Pharmaceuticals公布了2025年第二季度财报，现金及等价物增至430万美元。公司宣布两次季度现金股息，每股0.15美元，并与马来西亚FITTERS达成19.99%股权交换协议，后者将成为其全资子公司。同时，公司实施了1:15反向股票分割以符合纳斯达克要求。研发费用下降40%，至100万美元，净亏损收窄至130万美元。
08-13 20:05
Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally
After sharing encouraging preclinical results for a potential biliary tract cancer treatment, Cyclacel Pharmaceuticals jumped 34.56% to $13.20 in after-hours trading.
08-05 14:53
Reported Earlier, Cyclacel Announces New Findings Supporting Use Of Plogosertib In Biliary Tract Cancer Patients With High BUBR1 Expression
Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis
08-05 14:42
Cycle Pharmaceuticals Enters Exclusive U.S. Deal With Handa To Launch FDA-Approved Leukemia Drug PHYRAGO In September 2025
Cycle Pharmaceuticals (Cycle Pharma) has entered into an exclusive U.S. commercialization agreement with Handa Therapeutics, LLC (Handa), for PHYRAGO, an FDA approved drug for treating two types of leukemia, Philadelphia
07-21 21:28
